Trusted Resource for Clinical Trials, Protocols & Progress
TMF QC & Reconciliation SOP: Roles, Cadence, Checklists TMF QC and Reconciliation SOP: Defining Roles, Cadence, and Checklists that Pass Real Inspections Purpose and scope: a pragmatic SOP that proves control, not bureaucracy What “good” looks like for TMF QC and reconciliation A credible Trial Master File program is simple to explain and fast to…
Read More “TMF QC & Reconciliation SOP: Roles, Cadence, Checklists” »
TMF Timeliness SLAs & Thresholds: Audit-Ready Evidence TMF Timeliness SLAs & Thresholds: How to Produce Audit-Ready Evidence That Survives Live Inspection Why timeliness decides inspection outcomes—and how to make it measurable From “filed eventually” to “filed on time—and provably so” Regulators do not ask whether documents exist; they ask whether the Trial Master File (TMF)…
Read More “TMF Timeliness SLAs & Thresholds: Audit-Ready Evidence” »
Listings QC Checklist: Filters, Columns, Logic — No Last-Minute Fixes Listings QC That Doesn’t Break on Submission Day: Filters, Columns, and Logic You Can Defend Why listings QC is a regulatory deliverable, not a formatting chore The purpose of listings (and why reviewers open them first) Clinical data listings are where reviewers go when a…
Read More “Listings QC Checklist: Filters, Columns, Logic — No Last-Minute Fixes” »
Proven TMF KPIs for FDA/MHRA Inspection Readiness Proven TMF KPIs for FDA/MHRA Inspection Readiness: The Metrics, Methods, and Evidence That Survive Real Audits Why measurable TMF performance is the fastest path to inspection readiness Anchor your TMF to a small set of outcome-driven KPIs Inspectors don’t reward volume; they reward control. A Trial Master File…
Read More “Proven TMF KPIs for FDA/MHRA Inspection Readiness” »
Double Programming vs Peer Review: Risk-Based Verification Double Programming vs Peer Review: Choosing Risk-Based Verification that Survives Inspection Outcome-first verification: define the decision, then pick the method What success looks like for verification Verification is successful when a reviewer can select any number in any output, travel to the rule that produced it, and re-generate…
Read More “Double Programming vs Peer Review: Risk-Based Verification” »
Translational Packages: Nonclinical to First-in-Human—What FDA Expects Translational Packages for First-in-Human: What FDA Expects from Nonclinical Through Dose Justification Outcome-first translational strategy: how to earn confidence for first-in-human Define the decision you want the reviewer to sign Your first regulatory milestone is simple to state and hard to win: agreement that the available nonclinical evidence…
Read More “Translational Packages: Nonclinical to First-in-Human—What FDA Expects” »
Digital Health & SaMD in Trials: Do You Need an IDE or IND? Digital Health & SaMD in Clinical Trials: A Practical Guide to Choosing IDE vs IND and Writing an Inspection-Ready Rationale Outcome-first thinking: when does a digital tool trigger IDE vs IND—and why it matters to speed and scrutiny Start with the primary…
Read More “Digital Health & SaMD in Trials: Do You Need an IDE or IND?” »
US Oncology INDs: Safety Stopping Rules & DMC/DSMB Interfaces Designing Safety Stopping Rules and DMC/DSMB Interfaces for US Oncology INDs: A Practical, Inspection-Ready Playbook Why oncology trials live or die on their safety governance—and how to make it decisionable from Day 0 Begin with the decisions your trial must survive Oncology development stresses clinical safety…
Read More “US Oncology INDs: Safety Stopping Rules & DMC/DSMB Interfaces” »
ADaM Derivations You Can Defend: Versioning, Unit Tests, Rationale ADaM Derivations You Can Defend: Versioning Discipline, Unit Tests That Catch Drift, and Rationale You Can Read in Court Outcome-first ADaM: derivations that survive questions, re-cuts, and inspection sprints What “defensible” means in practice Defensible ADaM derivations are those that a new reviewer can trace, reproduce,…
Read More “ADaM Derivations You Can Defend: Versioning, Unit Tests, Rationale” »
CMC Stability & Specifications for IND: Phase-Appropriate Justification Phase-Appropriate CMC Stability and Specifications for IND: How to Justify What’s “Enough” Without Overbuilding Why phase-appropriate stability and specifications decide IND speed—and how to justify them Start with the decision you need FDA to make The immediate outcome for a US-first early development program is straightforward: acceptance…
Read More “CMC Stability & Specifications for IND: Phase-Appropriate Justification” »
